High-Risk Multiple Myeloma Patients Benefit from Aggressive Treatment
Posted: Apr 27, 2017
High-Risk Multiple Myeloma Patients Benefit from Aggressive Treatment image

Dr. Sagar Lonial of Emory University’s Winship Cancer Institute recently discussed his paper on how he treats high-risk myeloma with Dr. Neil Love of Research To Practice: An Integrated Approach to Oncology Education.

A big question for physicians, according to Dr. Lonial, was whether their patients “should they get maintenance therapy and what should they get as maintenance therapy?”  He also said “single agent maintenance therapy post auto [transplant] is not going to be sufficient.”

Two important considerations were “the importance of identifying who the high-risk people are at the time of diagnosis is important because if you miss that opportunity, you’re not going to know it until they’ve relapsed really early. The second is, make sure that you’re aggressive with their treatment and that you’re aggressive in their maintenance as well, because if you do that, you can ultimately improve their long-term outcomes.”

For high-risk patients “under treatment of myeloma is generally a bad thing.”  He added that physicians should “make sure that [they] are aggressive with…treatment and aggressive with maintenance as well…to ultimately improve…long-term outcomes.”

Watch the video interview here.

The author Greg Brozeit

about the author
Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811